Your session is about to expire
← Back to Search
Nilotinib for Preventing Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Study Summary
This trial is testing the side effects and best dose of nilotinib to prevent numbness and tingling caused by chemotherapy in stage I-III breast cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Group I (paclitaxel, nilotinib hydrochloride monohydrate)
- Group 2: Group II (paclitaxel, placebo)
Frequently Asked Questions
Has the FDA approved a combination of paclitaxel and nilotinib hydrochloride monohydrate for human use?
"Our experts at Power judged Group I (paclitaxel, nilotinib hydrochloride monohydrate) to be relatively unsafe with a score of 1 due to the limited evidence available from phase one trials that deem it both efficacious and safe."
Is this study currently accessible to participants?
"As indicated on the clinicaltrials.gov website, this research study is still in pursuit of participants. It was first published on December 11th 2020 and updated most recently on February 24th 2023."
How many individuals have taken part in this medical experiment?
"Correct. Per the information posted on clinicaltrials.gov, this study is presently recruiting participants as of February 24th 2023 and originally began seeking patients December 11th 2020. The trial requires up to 20 volunteers at one medical centre."
What therapeutic effects does Group I (paclitaxel, nilotinib hydrochloride monohydrate) typically produce?
"Group I (paclitaxel, nilotinib hydrochloride monohydrate) is a combination of drugs utilized to treat myeloid leukemia, chronic phase. Additionally, it may have beneficial effects on non-small cell lung cancer metastasis and refractory accelerated phase chronic myeloid leukemia."
What other research initiatives have been conducted that focused on the combination of paclitaxel and nilotinib hydrochloride monohydrate?
"Presently, there are 787 trials underway that specifically focus on Group I (paclitaxel, nilotinib hydrochloride monohydrate), with 219 in their final phase. Woolloongabba, Queensland is the epicentre of research for this group; however 43561 sites across the globe have studies related to it running at any given moment."
Share this study with friends
Copy Link
Messenger